The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase
Open Access
- 1 November 2013
- journal article
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 110 (3), 303-310
- https://doi.org/10.1016/j.ymgme.2013.08.002
Abstract
No abstract availableKeywords
Funding Information
- Shire
This publication has 12 references indexed in Scilit:
- Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher diseaseJournal of Immunological Methods, 2011
- Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndromeGenetics in Medicine, 2011
- Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)Journal of Inherited Metabolic Disease, 2009
- Initial report from the Hunter Outcome SurveyGenetics in Medicine, 2008
- Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)Pediatrics, 2008
- Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeuticsJournal of Immunological Methods, 2007
- A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genetics in Medicine, 2006
- ATS StatementAmerican Journal of Respiratory and Critical Care Medicine, 2002
- THE NATURAL HISTORY OF THE SEVERE FORM OF HUNTER'S SYNDROME: A STUDY BASED ON 52 CASESDevelopmental Medicine and Child Neurology, 1983
- The Defect in the Hunter Syndrome: Deficiency of Sulfoiduronate SulfataseProceedings of the National Academy of Sciences of the United States of America, 1973